Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Citius Pharmaceuticals ( (CTXR) ) is now available.
On June 9, 2025, Citius Pharmaceuticals entered into a securities purchase agreement with an institutional investor for a registered direct offering of common stock and pre-funded warrants, closing on June 11, 2025. The offering, facilitated by H.C. Wainwright & Co., raised approximately $6 million in gross proceeds, with net proceeds expected to support the commercial launch of LYMPHIR and other corporate purposes. The issuance included warrants exercisable at $1.00 per share, with potential additional proceeds of $9.8 million if fully exercised. The company agreed to restrictions on issuing additional shares for 60 days post-closing, with certain exceptions.
The most recent analyst rating on (CTXR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.
Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products. The company’s product portfolio includes LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma, Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief.
Average Trading Volume: 2,050,595
Technical Sentiment Signal: Sell
Current Market Cap: $10.91M
See more data about CTXR stock on TipRanks’ Stock Analysis page.